Basel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based radiopharmaceuticals that are used both for diagnostic imaging and therapeutic applications. The post Extra boost for Nuclidium: financing round reaches €115 million appeared first on European Biotechnology Magazine.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.